Literature DB >> 18097453

Prognostic false-positivity of the sentinel node in melanoma.

J Meirion Thomas1.   

Abstract

It is a basic tenet of the sentinel lymph-node biopsy procedure that all positive sentinel lymph nodes will inevitably progress to palpable nodal recurrence if not removed. Comparison of survival is, therefore, considered permissible among patients with positive sentinel lymph nodes who undergo early lymphadenectomy with that among patients who have delayed lymphadenectomy for palpable regional node metastasis, providing that survival is calculated from the date of wide local excision of the primary tumor. Here, that fundamental assumption is contested and evidence is presented to show that a positive sentinel lymph node might have no adverse prognostic relevance in up to one-third of patients. Furthermore, in the same patients, progression to palpable nodal disease might not have occurred even if the positive sentinel node had not been removed. The term prognostic false-positivity is used to describe this phenomenon. Such patients are incorrectly up-staged, are given inaccurate prognostic information and can undergo unnecessary completion lymphadenectomy and unnecessary adjuvant therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18097453     DOI: 10.1038/ncponc1014

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  17 in total

Review 1.  A review of sentinel lymph node biopsy for thin melanoma.

Authors:  K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan
Journal:  Ir J Med Sci       Date:  2014-11-01       Impact factor: 1.568

2.  Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma.

Authors:  Ettore Minutilli; Uwe Trefzer; Eggert Stockfleth; Wolfram Sterry
Journal:  Nat Clin Pract Oncol       Date:  2009-01

3.  Sentinel lymph node biopsy in malignant melanoma.

Authors:  J Meirion Thomas
Journal:  BMJ       Date:  2008-04-26

Review 4.  Lymph node dissection for melanoma: where do we stand?

Authors:  Madalyn G Neuwirth; Edmund K Bartlett; Giorgos C Karakousis
Journal:  Melanoma Manag       Date:  2017-03-03

Review 5.  Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Authors:  Athanassios Kyrgidis; Thrasivoulos Tzellos; Simone Mocellin; Zoe Apalla; Aimilios Lallas; Pierluigi Pilati; Alexander Stratigos
Journal:  Cochrane Database Syst Rev       Date:  2015-05-16

6.  Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial.

Authors:  Ingo Stoffels; Ken Herrmann; Jan Rekowski; Philipp Jansen; Dirk Schadendorf; Andreas Stang; Joachim Klode
Journal:  Trials       Date:  2019-02-04       Impact factor: 2.279

7.  Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention.

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-04-08       Impact factor: 66.675

8.  Melanoma: MSLT-1--putting sentinel lymph node biopsy into context.

Authors:  Vernon K Sondak; Jonathan S Zager
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

Review 9.  Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data.

Authors:  Yoichi Moroi
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

10.  The rationale for sentinel-node biopsy in primary melanoma.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson
Journal:  Nat Clin Pract Oncol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.